Inebilizumab
Inebilizumab Basic information
- Product Name:
- Inebilizumab
- Synonyms:
-
- Inebilizumab
- Research Grade Inebilizumab(DHD10802)
- Inebilizumab (anti-CD19)
- MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551
- Research Grade Inebilizumab
- CAS:
- 1299440-37-1
- MW:
- 0
- Mol File:
- Mol File
Inebilizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Inebilizumab Usage And Synthesis
Uses
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].
in vivo
Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2].
| Animal Model: | huCD19/CD20 double Tg mice[2] |
| Dosage: | 0.5, 2, or 10 mg/kg |
| Administration: | Tail vein injection, once |
| Result: | Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages. |
References
[1] Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5(12):107. DOI:10.3390/jcm5120107
[2] Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. DOI:10.1124/jpet.110.168062
InebilizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com